Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. (PBH) is listed on NYSE and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Tarrytown, United States and has 890 employees. The company is worth $2.34B and trades at 13.4x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $1.09B in fiscal 2026, down 4.3% from the year before. Net income was $190.3M. The share price is 30.4% below its 52-week high of $71.07. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $26.67M. In that quarter, 3 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -10.8% over 5Y.
today you would have $832.14▼ -16.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $49.92 | $61.69 | $78.09 | $61.22 | $62.60 | $60.65 | $34.87 | $40.50 | $30.88 | $44.41 | $52.10 | $51.48 | $34.72 | $35.80 | $20.03 | $11.27 | $11.95 | |
| P/E |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 3.8% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 18.7 across this company’s own years on record.
Cash flow growing 3.8% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | $17.33 | 7.4x | 3.7x | 0.00% | 66.12% | $2.31B |
| UFPTUfp Technologies Inc | $297.33 | 31.3x | 5.0x | 0.00% | 17.05% | $2.3B |
| MBXMBX Biosciences, Inc. | $49.61 | — | 5.8x | 0.00% | -33.17% | $2.39B |
| ADUSAddus HomeCare Corp | $122.67 |
| 18.7x |
| 12.8x |
| 14.4x |
| 18.7x |
| — |
| 15.5x |
| 18.7x |
| 12.5x |
| — |
| 4.9x |
| 34.2x |
| 27.7x |
| 34.6x |
| 25.0x |
| 28.2x |
| 27.4x |
| 19.4x |
| 18.7x |
| P/S | 2.7x | 2.2x | 2.7x | 3.5x | 2.7x | 2.9x | 3.2x | 1.8x | 2.1x | 1.6x | 2.7x | 3.4x | 3.8x | 3.0x | 3.0x | 2.3x | 1.7x | 2.0x |
| P/B | 2.1x | 1.3x | 1.7x | 2.4x | 2.1x | 2.0x | 2.2x | 1.5x | 1.9x | 1.4x | 2.9x | 3.7x | 4.3x | 3.2x | 3.8x | 2.5x | 1.6x | 1.8x |
| EPS | $3.91 | $4.29 | $4.17 | -$1.65 | $4.04 | $3.25 | $2.78 | -$0.69 | $6.34 | $1.30 | $1.88 | $1.49 | $1.39 | $1.27 | $0.73 | $0.58 | $0.64 |
| Profit margin | 12.16% | 17.48% | 18.86% | 18.60% | -7.30% | 18.90% | 17.46% | 14.77% | -3.67% | 32.61% | 7.87% | 12.39% | 10.95% | 12.16% | 10.56% | 8.44% | 8.68% | 10.98% |
| ROE | 12.12% | 10.08% | 11.70% | 12.65% | -5.69% | 13.02% | 12.12% | 12.15% | -3.27% | 28.81% | 8.44% | 13.42% | 12.47% | 12.89% | 13.71% | 9.24% | 8.08% | 9.76% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
+33.0% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 20.7x |
| 2.0x |
| 0.00% |
| 9.71% |
| $2.29B |
| PGENPrecigen Inc | $6.39 | — | 52.4x | 0.00% | -837.08% | $2.29B |
| MDPediatrix Medical Group, Inc. | $29.55 | 14.1x | 2.7x | 0.00% | 20.39% | $2.4B |